Zacks: Analysts Anticipate Abbott Laboratories (NYSE:ABT) Will Announce Earnings of $1.34 Per Share

Equities analysts expect Abbott Laboratories (NYSE:ABT) to post earnings of $1.34 per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for Abbott Laboratories’ earnings, with the lowest EPS estimate coming in at $1.26 and the highest estimate coming in at $1.43. Abbott Laboratories posted earnings of $0.65 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 106.2%. The firm is expected to issue its next earnings report on Thursday, April 15th.

According to Zacks, analysts expect that Abbott Laboratories will report full year earnings of $5.07 per share for the current financial year, with EPS estimates ranging from $5.00 to $5.24. For the next year, analysts expect that the company will post earnings of $5.33 per share, with EPS estimates ranging from $4.20 to $5.63. Zacks’ earnings per share averages are an average based on a survey of research firms that follow Abbott Laboratories.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Tuesday, January 26th. The healthcare product maker reported $1.45 earnings per share for the quarter, beating analysts’ consensus estimates of $1.35 by $0.10. Abbott Laboratories had a net margin of 10.50% and a return on equity of 18.19%. The business had revenue of $10.70 billion during the quarter, compared to the consensus estimate of $9.94 billion. During the same quarter in the prior year, the firm earned $0.95 EPS. The company’s revenue for the quarter was up 28.7% compared to the same quarter last year.

A number of equities research analysts recently weighed in on the stock. SVB Leerink boosted their price objective on shares of Abbott Laboratories from $115.00 to $128.00 and gave the company a “market perform” rating in a research report on Thursday, January 28th. Wells Fargo & Company boosted their target price on shares of Abbott Laboratories from $128.00 to $137.00 in a research note on Thursday, January 28th. Morgan Stanley boosted their target price on shares of Abbott Laboratories from $126.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday, January 28th. Raymond James boosted their target price on shares of Abbott Laboratories from $114.00 to $126.00 and gave the company an “outperform” rating in a research note on Thursday, January 28th. Finally, Zacks Investment Research raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $130.00 target price for the company in a research note on Tuesday, February 2nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and sixteen have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $122.26.

In related news, SVP Joseph J. Manning sold 18,750 shares of the business’s stock in a transaction that occurred on Monday, February 1st. The shares were sold at an average price of $122.79, for a total value of $2,302,312.50. Following the sale, the senior vice president now directly owns 81,561 shares in the company, valued at approximately $10,014,875.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Phebe N. Novakovic sold 4,790 shares of the business’s stock in a transaction that occurred on Friday, December 4th. The stock was sold at an average price of $107.28, for a total transaction of $513,871.20. Following the completion of the sale, the director now owns 34,446 shares in the company, valued at $3,695,366.88. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 24,045 shares of company stock valued at $2,881,071. Company insiders own 1.70% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Atlas Private Wealth Advisors raised its holdings in shares of Abbott Laboratories by 107.3% in the 4th quarter. Atlas Private Wealth Advisors now owns 228 shares of the healthcare product maker’s stock worth $25,000 after purchasing an additional 118 shares in the last quarter. Stuart Chaussee & Associates Inc. bought a new stake in shares of Abbott Laboratories in the 3rd quarter worth approximately $29,000. Inspire Advisors LLC bought a new stake in shares of Abbott Laboratories in the 4th quarter worth approximately $29,000. Price Wealth LLC raised its holdings in shares of Abbott Laboratories by 63.6% in the 3rd quarter. Price Wealth LLC now owns 306 shares of the healthcare product maker’s stock worth $33,000 after purchasing an additional 119 shares in the last quarter. Finally, Black Swift Group LLC acquired a new stake in shares of Abbott Laboratories during the fourth quarter valued at approximately $35,000. Institutional investors and hedge funds own 72.58% of the company’s stock.

Shares of NYSE:ABT traded down $0.65 during trading on Thursday, reaching $121.90. 63,180 shares of the company’s stock traded hands, compared to its average volume of 5,381,432. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.70 and a quick ratio of 1.19. Abbott Laboratories has a 12 month low of $61.61 and a 12 month high of $128.54. The company has a 50 day moving average of $118.10 and a 200-day moving average of $109.83. The stock has a market capitalization of $216.05 billion, a P/E ratio of 64.84, a price-to-earnings-growth ratio of 2.06 and a beta of 0.83.

The business also recently declared a quarterly dividend, which will be paid on Monday, May 17th. Stockholders of record on Thursday, April 15th will be paid a $0.45 dividend. This represents a $1.80 dividend on an annualized basis and a dividend yield of 1.48%. The ex-dividend date is Wednesday, April 14th. Abbott Laboratories’s dividend payout ratio is currently 55.56%.

About Abbott Laboratories

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. Its Established Pharmaceutical Products segment offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.

Further Reading: Earnings Per Share

Get a free copy of the Zacks research report on Abbott Laboratories (ABT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.